Clinical Trial Update: Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP) [Phase 2]

View source ↗

Summary

This notice reports the completion of a Phase 2 study of SKI-O-703, a SYK inhibitor, in persistent and chronic immune thrombocytopenia and that results have bee…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• SKI-O-703 (SKI-O-703)

Snippet

Sponsor: Oscotec Inc. | Conditions: Immune Thrombocytopenia | Phase 2 | Status: COMPLETED | Results posted: 2024-07-10